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Globin mRNA reduction for whole-
blood transcriptome sequencing
Kaarel Krjutškov1,2,3, Mariann Koel2,4, Anne Mari Roost2, Shintaro Katayama1, 
Elisabet Einarsdottir1,3, Eeva-Mari Jouhilahti1, Cilla Söderhäll1,5, Ülle Jaakma2,6, Mario Plaas7, 
Liselotte Vesterlund1, Hannes Lohi3, Andres Salumets2,7,8,9 & Juha Kere1,3
The transcriptome analysis of whole-blood RNA by sequencing holds promise for the identification and 
tracking of biomarkers; however, the high globin mRNA (gmRNA) content of erythrocytes hampers 
whole-blood and buffy coat analyses. We introduce a novel gmRNA locking assay (GlobinLock, GL) as a 
robust and simple gmRNA reduction tool to preserve RNA quality, save time and cost. GL consists of a 
pair of gmRNA-specific oligonucleotides in RNA initial denaturation buffer that is effective immediately 
after RNA denaturation and adds only ten minutes of incubation to the whole cDNA synthesis 
procedure when compared to non-blood RNA analysis. We show that GL is fully effective not only for 
human samples but also for mouse and rat, and so far incompletely studied cow, dog and zebrafish.
As a type of liquid biopsy, blood is widely used in clinical research due to its ease of sampling, its transport of bio-
molecules from all over the body and its rapid dynamics. Blood carries proteins, metabolites and cells, and cells 
such as erythrocytes, leukocytes and platelets can provide genomic DNA, microRNA and mRNA as biomarkers 
for a number of applications1–3. Using whole-blood RNA (wbRNA) for expression profiling by RNA-sequencing 
(RNA-seq) involves challenges such as a low proportion of leukocytes (4–11 × 106/l) and a high prevalence of 
erythrocytes (4–5 × 109/l), resulting in a significant amount of globin mRNAs (gmRNA) from erythrocytes. As 
a result, the wbRNA pool is enriched with gmRNA to the extent that 50–80% of the wbRNA-seq reads map to 
gmRNA4,5. This high prevalence of gmRNA complicates transcriptome studies of wbRNA, as the massive con-
version of gmRNA molecules to globin cDNA (gcDNA) hijacks a significant portion of cDNA synthesis power 
while simultaneously leaving biologically relevant molecules undetectable. The available gmRNA reduction 
methods for RNA-seq, including GLOBINclearTM (ThermoFisher) and Globin-ZeroTM (Illumina), help overcome 
this limitation but also add more hands-on steps, thereby compromising the quality of the RNA (reviewed in 
Supplementary Fig. 1).
In adult humans, highly expressed gmRNA alpha 1 and 2 (HBA, hereafter α ) and beta (HBB, β ) gmRNAs are 
unusually stable to ensure continuous hemoglobin protein expression in differentiated erythrocytes6. The cellular 
stability of gmRNA is explained in part by a closed loop structure, a characteristic shared by almost all eukaryotic 
mRNAs. Specifically, the gmRNA contains a cis-acting sequence, C-rich element in its 3′ untranslated region, and 
a 5′ m7 Gppp cap structure, which are critical for the stability of this long-lived mRNA7,8.
To reduce the abundance of gmRNA in gene expression-based studies, we systematically evaluated a number 
of gmRNA-specific oligonucleotides (GlobinLock, GL) that prevent or at least significantly reduce the priming of 
gcDNA synthesis. Our GL approach reduces the negative effects of gmRNA presence in expression studies and 
eliminates the need for additional pipetting. For adult human with dominating gmRNA α and β , a single pair of 
specific oligonucleotides in RNA denaturation buffer is used. The GL is effective immediately after RNA denatura-
tion by binding to gmRNA molecules at 3′ site and specifically blocking the binding site of oligo-T primer. The GL 
mediated gmRNA reduction procedure adds only ten minutes of incubation to the cDNA synthesis procedure.
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Results and Discussion
We observed that oligonucleotide hybridization with gmRNA masks the binding site of the anchored oligo-T 
primer (T30VN, oligonucleotides are shown in Supplementary Table 1), suppressing gcDNA synthesis. The 
anchored oligo-T primer has degenerated nucleotide(s) at 3′ end to determine cDNA priming at single posi-
tion per transcript9,10. Non-anchored oligo-T primers anneal randomly along 150–250 poly-A nucleotide tail of 
mRNA11, producing multiple cDNA molecules from a single template mediated by strand replacement activity of 
reverse transcriptase (RT).
To discover the most effective and specific GL, multiple oligonucleotide variants that are complementary to 
human globin α and β were tested. Two types of GL oligonucleotides were designed: a linear GL masking the 
3′ end of gmRNA and a circular GL masking the gmRNA 3′ with an additional binding site at the 5′ end to add 
specificity and to interfere with the opening of the gmRNA secondary structure. The natural shape of gmRNAs, 
where the 3′ and 5′ ends are in close proximity (Supplementary Figs 2 and 3) enabled the hypothetical formation 
of a circular gmRNA with a circular GL complex prior to cDNA synthesis (Fig. 1a).
The GLs were first evaluated by quantitative PCR (qPCR), measuring the yield change of α cDNA. HBA has 
predicted secondary structure at gmRNA 3′ end by two independent algorithms (Supplementary Figs 2 and 3). 
Therefore the predicted α self-binding compete with GL, indicating that sensitive test system should be used to 
ascertain efficient and stringent hybridization and oligonucleotide conditions for comprehensive gmRNA lock-
ing. To investigate stable binding and blocking properties of GL oligonucleotides, we tested locked nucleic acid12 
(LNA) and zip nucleic acid13 (ZNA) modifications in addition to non-modified DNA oligonucleotides. In a par-
allel comparison, ZNA-modified GL provided the highest gcDNA reduction fold change (8.3 ± 1.1) and was more 
efficient than 3′ -LNA and 3′ -DNA long oligonucleotides (Fig. 1b). As the predicted secondary structure of α 
masks the gmRNA 3′ end for GL hybridization, the blocking is highly dependent on GL concentration, providing 
the highest fold change at the 5 μ M level (Fig. 1c). Higher GL concentrations were not tested due to the possible 
risk of inhibition to immediate downstream cDNA synthesis in the same reaction tube.
Despite the micromolar concentration of GL, the specificity in gcDNA reduction was verified by the addi-
tion of artificial spike-in molecules at 1, 50 and 100 ng of input wbRNA. The spike-in is pre-formulated set of 92 
polyadenylated artificial mRNA-like molecules at different concentrations to enable up to date expression data 
normalization. In GL specificity test, GL oligonucleotides had no binding sites on spike-in molecules, enabling to 
evaluate the GL’s specificity. As a result, we found no differences in spike-in detection (P ≥ 0.107, n = 3, Student’s 
t-test, Supplementary Table 2) at different wbRNA concentrations in the presence of GL, indicating that only up 
to 10 additional PCR cycles were required to analyze 1 ng of wbRNA instead of 100 to compensate for the lower 
input material (Fig. 2a). Without RNA-seq proofs, the theoretical wbRNA input requirement for GL is > 10 times 
less than for GLOBINclearTM or Globin-ZeroTM kits, as reviewed in Supplementary Fig. 1. In addition to speci-
ficity, GL efficiency was evaluated at 1–100 ng wbRNA range by qPCR. As a result, α and β reduction fold change 
increased slightly using higher amount of input RNA in this test system (Fig. 2b).
Figure 1. The nature and reduction effect of GlobinLock. (a) Schematic globin mRNA with possible 
masking oligonucleotides and anchored oligo-T primer. All oligo sequences and modifications are shown in 
Supplementary Table 1. (b) Five GL conditions and GL-negative controls were compared to measure globin α 
reduction fold change by qPCR. Template dilutions (10× ) were used in this relative qPCR design and therefore 
the reduction effect up to ten is measured accurately according to existing dilution factor but fold change values 
above ten are out of the reported quantification range. (c) 3′ -DNA long GL concentration effect on human 
globin α and β as measured by qPCR.
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The specificity of GL was measured also by RNA-seq where different GL conditions were compared with 
GL negative samples. For all GL oligos, the spike-in experiment indicated high correlations. Still in 3′ -LNA 
(R = 0.998) and 3′ -DNA long GL (R = 0.997) higher specificity was seen than using 3′ -DNA short GL (R = 0.974) 
and 3′ -ZNA (R = 0.875) (Fig. 2c).
The presence of the GL oligo T-tail is critical for efficient masking of gmRNA. The minimum length of T-tail 
was verified by experiments where gradually shorter oligonucleotides were compared. The GL with T15 was used 
as a control and compared with the T4, T2, and T0 GL oligonucleotides. A minimum of 4 T nucleotides was 
required to enable a stable masking complex prior to T30VN hybridization (Fig. 2d). It has been shown that once 
initiated, gcDNA synthesis can be inhibited only by peptide nucleic acid oligonucleotides14 (PNA), as any other 
downstream hybridized DNA or LNA molecules are removed by the strand-displacement activity of RT15.
The global GL effect for seven wbRNAs and one negative control over all conditions was analyzed using a 
modified single-cell tagged reverse transcription RNA-seq method9,16 (STRT). The STRT uses oligo-T priming 
similar to advanced SMART-Seq protocols17, G&T-seq18 and CEL-seq19 protocols. The wbRNA was diluted to 
30 ng/μ l, and 2 μ l was treated for 10 min at 60 °C in the presence of GL in GL-K+ buffer prior to cDNA synthesis. 
The presence of K+ cation is essential for stringent GL hybridization and is harmless for downstream RT reaction 
in the same reaction tube. Alkaline pH ensures the stability of mRNAs even after the short denaturation and 
blocking. It is notable that brief denaturation at 95 °C is essential for GL mediated locking reaction due to the 
presence of K+, elevating probably the annealing temperature of target gmRNA molecules. Only constant GL 
hybridization time and temperature (10 min at 60 °C) was tested by RNA-seq experiment in this report. Based on 
the nature of gmRNA and our empirical data about high GL concentration dependence, GL hybridization seems 
to take place just after gmRNA denaturation and before gmRNA forms its natural closed structure. Therefore 
shorter locking incubation times are rationale to test by RNA-seq.
All different GL oligonucleotide reactions were compiled into one 48-plex RNA-seq library. The library was 
sequenced on one Illumina HiSeq2000 lane, obtaining 0.9–4.1 M qualified reads per sample according to the 
type of GL oligo (Supplementary Table 3). The read mapping rate to reference was 88–92%. Our applied STRT 
RNA-seq method9 determines the 5′ start site of poly-A transcript, indicating the possible RNA degradation. 
Therefore the mRNA 5′ -capture rate (RNA integrity) in GL experiment was 80–85% for all conditions, showing 
that the proportion of the mapped and intact transcripts was not decreased after GL treatment (Supplementary 
Table 3).
RNA-seq without GL treatment revealed a 63.6% total prevalence of globin transcripts, with α and β contrib-
uting by 21.4% and 42.2%, respectively (Fig. 3a). Similar to our observations, surprisingly high variation in globin 
levels between studied samples was also described in previous report4, where globin prevalence differed between 
52–76% over six samples. This difference is most likely representing the variable erythrocyte count in the original 
Figure 2. The effective range and limitations. (a) qPCR cycle threshold values are presented to indicate 
the number of required PCR cycles if less than 100 ng of whole-blood RNA is GL treated. (b) GL fold change 
reduction effect was measured by qPCR for three whole-blood RNA inputs: 1, 50 and 100 ng. (c) Scatter plot to 
measure the GL specificity based on an ERCC 92 mRNA spike-in mix over five different GL oligonucleotides 
compared with a GL-negative control. (d) The importance of the GL Tn tail for masking. Different GL 
oligonucleotides with variable lengths of Tn tails were analyzed, and the reduction effect of globin α was 
compared with the GL-negative experiment using qPCR.
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blood samples; the information which was not available for our study participants. β cDNA synthesis was reduced 
by ~90× (from 42.2% to 0.5%) by LNA-modified GL oligos, and α was reduced by ~4.5× (21.4% to 4.7%) by 
3′ -LNA or 3′ -DNA long GL. However, the prevalence of α and β was reduced by > 10× (63.6% to 5.2%) in a com-
bination where 3′ -LNA and 3′ -DNA long or only 3′ -LNA GLs were used for β and α , respectively. The modest 
reduction effect of α (4.5× ) is explained by secondary structure of gmRNA. Compared with the β mRNA, in 
which the last 26–28 bp at the 3′ end are predicted to be free of self-assembling, potentially enabling efficient GL 
hybridization, α mRNA has a tight self-binding structure, making GL binding more competitive (Supplementary 
Figs 2 and 3).
Analyzing human wbRNA samples, 9,758 genes were detected in total. Without the GL treatment, 488 genes 
were uniquely detected (Fig. 3b). These genes showed normalized mean read count values at a frequency of 
1 × 10−5, indicating the random and scarce appearance of the genes (Supplementary Table 4). The top 10 tran-
scripts were analyzed by BLASTN at their 3′ -ends, but no significant similarities with GL sequences were detected. 
A slightly higher gene detection rate in GL treatment compared with the GL-negative sample was expected4,5. The 
normalized read count (~1 × 10−5) revealed that the detection of an additional 1,178 genes (Fig. 3b) was random 
based on the low read count per transcript. The genes detected, as well as their normalized prevalence and 95% 
confidence intervals, are shown in Supplementary Table 5.
A normalized read count comparison of the five different GL oligonucleotides with the GL-negative control 
RNA samples revealed a R ≥ 0.915 correlation (Fig. 3c), indicating the correlation of the rest of the thousands of 
transcripts after removing α and β from the analysis.
The high prevalence of globin mRNA in blood samples is a technical limitation for expression analysis in all 
animal species. Therefore, we designed 3′ -DNA long type GLs for cow, dog, rat, mouse and zebrafish. Zebrafish 
yield only 10–20 μ l of blood, making the amount of blood a limiting factor for wbRNA studies. The efficiency of 
GL in all species was tested by qPCR, quantifying the yield of gcDNA. A > 5× fold reduction was detected in all 
species except for cow α , dog α and zebrafish β (Supplementary Fig. 4). Sanger re-sequencing of dog and zebrafish 
at the ultimate 3′ end of gmRNA suggested the existence of a possible additional motif (AGCCT, Supplementary 
Table 6) in dog α 1. Simultaneously, no dog α 2 was detected. This finding may be explained by the 84% GC con-
tent in the last 50 bp of the gmRNA region that could potentially suppress simultaneous α 1 and α 2 amplification 
prior to cloning. Three of 10 independent clones identified a possible TAAAAGC motif deletion in zebrafish β . 
We suggest that high-quality re-sequencing of globin mRNAs, in particular at the most 3′ downstream region, 
may be needed for GL assay design in many model organisms.
In conclusion, here we present a simple and cost-effective method to overcome globin mRNA caused limi-
tation in biomarker research when whole-blood RNA samples are used. Presented data obtained by qPCR and 
RNA-seq proofs the GL positive reduction effect with adult human whole-blood RNA samples and indicates its 
potential for species as mouse, rat, cow, dog and zebrafish.
Methods
Ethics statements. The study protocol of human samples was approved by the Research Ethics Committee 
of the University of Tartu (221/M-31). Written informed consent was obtained from all analyzed persons. All 
experiments were performed in accordance with relevant guidelines and regulations.
Figure 3. Reduction outcome. (a) Human globin α and β mRNA reduction fold change based on the 
normalized prevalence over all genes detected in RNA-seq, with or without GL (red). (b) Venn diagram 
showing the total number of genes detected with or without GL treatment, where GL treatment revealed 1,178 
unique genes when compared with the control. (c) Whole-blood RNA transcriptome normalized read count 
comparing five different GLs with a GL-negative control.
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All methods with animal blood samples were performed in accordance with the European Communities 
Directive (86/609/EEC) guidelines and regulations. The used experimental protocols were approved by Animal 
Clinic of the Estonian University of Life Sciences (Estonian Veterinary and Food Board (KL1203)), the Animal 
Ethics Committee of State Provincial Office of Southern Finland (ESAVI/6054/04.10.03/2012) and the Stockholm 
North Experimental Animal Committee (N128/15).
RNA secondary structure prediction. Human RefSeq HBA1 (α ), HBA2 (α ), and HBB (β ) mRNA 
sequences with additional A5 nucleotides at 3′ to mimic the poly-A strand were used to predict secondary struc-
tures. Two structure prediction software packages, mfold v3.620 and The Vienna RNA Websuite21, were used 
(Supplementary Figs 2 and 3).
GlobinLock design. The GL molecule is a single strand DNA (Sigma Aldrich), LNA (Exiqon) or ZNA 
(Metabion) oligonucleotide with 3′ modification to block possible 3′ extension during enzymatic reactions. All 
oligonucleotides are shown in Supplementary Table 1. Based on the gmRNA sequence, two types of GL molecules 
were designed. The circular GL (3′ -5′ -DNA, Fig. 1a) has two complementary sequences to gmRNA. The 5′ end 
of circular GL binds to the mRNA 5′ end, covering 22 bp of α and 30 bp of β . The circular GL 3′ end binds to the 
gmRNA 3′ end to 28 bp of α and 31 bp of β to achieve similar Tm over all the specific regions. The circular GL 
has a 15 bp poly-T tail to bind and flank the 5′ end of the mRNA poly-A. The poly-T, together with the GL spe-
cific upstream region, form the core of the GL oligo that flanks the binding site of the anchored oligo-T primer 
(T30VN) prior to RT. A nonspecific linker with a variable length (55 bp of α and 44 bp of β ) is used to connect 
the GL oligo 5′ and 3′ specific regions and to form a circular complex between GL and gmRNA. The linear GL 
(3′ -ZNA/LNA/DNA short and long GL) were designed to mask only the T30VN priming site. The linear GL oligos 
contain up to 30 bp at the 3′ end that are specific to the gmRNA 3′ protein coding end and a ≤ 15 bp poly-T stretch 
complementary to the mRNA poly-A tail. The 3′ end of linear GL is blocked by phosphate to prevent enzymatic 
extension. The linear GL binds only at the 3′ site of gmRNA, forming no circular complex of GL and gmRNA.
Blood sampling and RNA extraction. Blood samples from humans (n = 7), cows (n = 3), dogs (n = 2), 
rats (n = 3), and mice (n = 6) were collected into PAXgene Blood RNA tubes (PreAnalytiX). The wbRNA of 
zebrafish (10–20 μ l) was collected and extracted immediately by the TRIzol method. For species other than mouse 
and zebrafish, 2.5 ml of blood was collected. For mouse samples, blood samples from several animals were pooled 
to obtain the required (2.5 ml) volume. All PAXgene samples were incubated for 24 h at room temperature prior 
to PAXgene Blood RNA Kit extraction, according to the manufacturer’s instructions. RNA concentrations and 
the RNA integrity number (RIN) were measured with an Agilent 2100 Bioanalyzer Total RNA Nano kit (Agilent 
Technologies) or Qubit Fluorometer (Thermo Fisher Scientific).
GlobinLock efficiency by quantitative PCR (qPCR). RT was performed on all RNA samples for sub-
sequent quantification with qPCR. During the cDNA synthesis, various GL molecules for different species or 
modifications (Supplementary Table 1) were added to the reaction mix to inhibit RT of α and β gmRNA mole-
cules. Another reaction mix contained nuclease-free water instead of GL and served as a negative control and a 
comparison for determining the oligonucleotide masking effect in qPCR. Globin mRNA masking reactions were 
then carried out using GL-K+ buffer containing 1 μ l of 50% PEG-6000 (Sigma Aldrich), 1.5 μ l of 3.2 M betaine 
(Sigma), 0.4 μ l of 25 mM dNTP mixture (Thermo), 0.375 μ l of 2 M KCl (Sigma), 0.05 μ l of 1 M Tris-HCl (Sigma, 
pH 8.0) and 0.05 μ l of 10% Triton X-100 (Sigma) per blocking reaction. For α and β globin blocking, 0.12 μ l of 
each specific 3′ -DNA long GL oligonucleotide (100 μ M) was added to each reaction, and an equal amount of 
nuclease-free water was used for negative controls. Nuclease-free water was added to obtain a final volume of 4 μ l.
Two microliters of wbRNA (20 ng/μ l) were added to 4 μ l of GL-K+ buffer and kept on ice until denaturation. 
The gmRNA masking and cDNA synthesis reactions were performed in 0.2-ml tubes using common thermo-
cyclers. The reaction conditions were as follows: 95 °C for 30 s for initial denaturation, 60 °C for 10 min for GL 
oligo hybridization and a 42 °C hold for the loading of 5 μ l of RT mixture. The 5 μ l of RT mixture contained 2 μ l 
of nuclease-free water, 0.04 μ l of 100 μ M T30VN, 1.6 μ l of 3.2 M betaine, 0.5 μ l of 1 M Tris-HCl (pH 8.0), 0.075 μ l 
of 1 M MgCl2 (Sigma), 0.5 μ l of 100 mM DTT (Sigma), 0.18 μ l of RiboLock RNase Inhibitor (Thermo), and 0.13 μ l 
of RevertAid Premium Transcriptase (Thermo). The concentrations were calculated for the final RT volume of 
10 μ l, including the GL-K+ buffer. Cycling parameters continued at 42 °C for 60 min for the RT reaction and 85 °C 
for 5 min for RT inactivation. Quantitative PCR was conducted using HOT FIREPol EvaGreen qPCR Mix Plus 
(ROX) (Solis BioDyne) with a 7500 Fast Real-Time PCR instrument (Applied Biosystems) according to the man-
ufacturer’s instructions; 200 nM primers and 1 μ l of template were used in a 20 μ l reaction volume. The primers 
were designed using Primer3 v4.0.0 software22. The generation of specific products was ensured by performing a 
melting curve analysis of the samples during the real-time PCR program. We also performed conventional PCR 
for all globin primers and analyzed the products with 2% TAE buffered agarose gel electrophoresis. All samples 
were also run with 10× diluted cDNA to enable quantification. The thermal cycling conditions were as follows: 
95 °C for 15 min for activation and then 30 cycles of 95 °C for 15 s, 62 °C for 20 s, 72 °C for 30 s (at the end of which 
the fluorescence was measured). The qPCR data were analyzed using Applied Biosystems 7500 Software v2.0.5.
GlobinLock effect by RNA-seq. The modified STRT method was used. Human wbRNA samples were 
diluted with RNase-DNase-free water to a concentration of 30 ng/μ l, and 2 μ l was added to 4 μ l of GL-K + buffer. 
The buffer contained 1 M betaine, 2 mM dNTP mixture, 10 mM Tris (pH 8.0), 150 mM KCl, 0.2% Triton X-100, 
2 μ M equimolar barcoded 48-plex template switching oligonucleotides, and 5 μ M GL α and β oligonucleotides 
(Supplementary Table 1). The human wbRNA samples (n = 7) were placed in the 48-plex reaction plate, and each 
well was tagged for sequencing with an individual barcode. After mixing GL-K+ and RNA on ice, the RNA was 
denatured for 30 s at 95 °C and incubated for 10 min at 60 °C for GL masking and continued for 60 min at 42 °C. 
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Just after the 60 °C incubation, the block was cooled to 42 °C, and 5 μ l of RT mixture was added to initiate cDNA 
synthesis. The RT mixture contained 1 M betaine, 50 mM Tris (pH 8.0), 5 mM DTT, 7.5 mM MgCl2, RiboLock 
(0.7 U/μ l), 400 nM T30VN and RevertAid Premium reverse transcriptase (7 U/μ l). The concentrations were calcu-
lated for final RT in a volume of 10 μ l, including the GL-K+ buffer. Two microliters of ERCC Mix 1 (Ambion), a 
1:500 spike-in dilution with nuclease-free water, were used per whole 48-plex library. After a 60-min RT reaction 
at 42 °C and a 5 min inactivation of RT at 85 °C, the contents of all 48 reaction wells (~500 μ l) were pooled into a 
2.0-ml tube. Dynabeads MyOne C1 Streptavidin (Invitrogen, 100 μ l) beads were washed twice and used to capture 
the formed cDNA molecules (and free primers) according to the instructions. After three rounds of EB buffer 
(10 mM Tris, pH 8.0) and one round of water washing, the DNA-enriched beads were suspended in 75 μ l of water 
and incubated at 75 °C for 3 min to release biotin from the streptavidin beads. The supernatant was used as a tem-
plate for further full cDNA amplification as described previously16. The purified cDNA pool was first amplified 
using 14 cycles of PCR followed by 15 additional cycles to introduce the complete sets of adapters for Illumina 
sequencing. The libraries were size-selected (200–400 bp) using the sequential AMPure XP bead selection proto-
col described previously16.
RNA-seq data analysis. Preprocessing of the RNA-seq raw sequences, alignment and quantitation were 
performed using the STRTprep pipeline16 (https://github.com/shka/STRTprep). The pipeline reports only 
uniquely mapped reads. The two loci HBA1 and HBA2 are highly similar and led to unmappable reads. Therefore, 
the HBA2 locus and the upstream 500 bp (chr16:222346-223709 on hg19 reference genome) were masked before 
alignment, resulting in the mapping of both HBA1 and HBA2 reads at HBA1. Branch v3dev (commit 698fa8c… ) 
was used as the standard procedure with PCR-bias reduction based on the unique molecular identifier (UMI) and 
branch v3devNoUMI (commit e0d6721… ) was a special procedure that skips the reduction step. The figures were 
generated using R version 3.2.2.
GlobinLock design for other species and Sanger re-sequencing. In addition to human, the GL oli-
gos were designed to mask gmRNA of cow, dog, rat, mouse, and zebrafish. For those species, qPCR-based quan-
tification was used, and linear GL oligonucleotides were applied. The GL design followed the principle that the 
specific part has a Tm ~70 °C plus an additional 15 bp poly-T tail to stabilize the complex during T30VN priming 
and cDNA synthesis. The qPCR-based GL efficiency was detected as described above. Due to the inability to 
detect the GL effect with α of cow and dog, and β of zebrafish (Supplementary Fig. 4), the gmRNA 3′ ends were 
amplified from cDNA, cloned to a vector and Sanger re-sequenced to confirm the sequence of the studied tran-
scripts. Briefly, the transcripts were amplified using primers indicated in Supplementary Table 1 and HotStarTaq 
DNA polymerase (Qiagen) according to manufacturer’s instructions. The products were amplified using a PCR 
program as follows: 95 °C for 5 min and 30 cycles of 95 °C for 30 s, 60 °C for 30 s, 72 °C for 30 s and final exten-
sion 72 °C for 5 min. PCR products were cloned into a pCRII-dual promoter TOPO vector using the TOPO TA 
cloning kit (Invitrogen) and sequences were verified by Sanger sequencing (Eurofins Genomics). The full Sanger 
sequences are available in Supplementary Table 7.
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